CJC‑1295/Ipamorelin (5/5mg)

This dual‑peptide preparation contains CJC‑1295 and Ipamorelin in equal amounts to support investigations into coordinated modulation of growth hormone–linked pathways. In vitro protocols often apply this blend in pituitary, endocrine, or metabolic models to characterize secretagogue effects, receptor interactions, and downstream biochemical outcomes under controlled conditions.
​​
Key details:
Peptides: CJC‑1295 and Ipamorelin
Content: 5 mg/5 mg lyophilized
Intended use: In‑vitro laboratory research only